See how TIM-3 expression may be causing widespread complications in HR-MDS and AML2,3

what contributes to complexity of HR-MDS and AML
What’s missing from current treatment approaches?
what is the role of TIM-3 expression

AML, acute myeloid leukemia; HR-MDS, higher-risk myelodysplastic syndrome; TIM-3, T cell immunoglobulin and mucin domain-3.

References: 1. Wang C, Yang Y, Gao S, et al. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies. Crit Rev Oncol Hematol. 2018;122:123-132. 2. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989-1004. 3. Kikushige Y, Shima T, Takayanagi S-I, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7(6):708-717.

This is a global website and is intended for health care professionals. The information on this site is intended for educational purposes only and is not country-specific.


Use of website is governed by the Terms of Use and Privacy Policy.

Copyright © 2021 Novartis AG. All rights reserved.

6/21 112789-1